Onglyza licence extended for use in combination with insulin

Onglyza (saxagliptin) can now be prescribed in combination with insulin for adults with type 2 diabetes, with or without metformin, when diet and exercise plus insulin alone do not provide adequate glycaemic control.

In a randomised, double-blind, placebo-controlled study (n=455), saxagliptin added to insulin therapy (with or without metformin) in patients with inadequate glycaemic control significantly reduced HbA1c and postprandial glucose levels compared with placebo at week 24. In an extension of the initial study, saxagliptin maintained the reduction in HbA1c levels at week 52 compared with placebo.

View Onglyza drug record

Further information: BMS/AstraZeneca

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

A man with his sleeves rolled up sits in a bare room heating heroin in a spoon over a lighter flame.

New implant treats opioid dependence for 6 months

Patients with opioid dependence can now be given a...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...